tbuckley/cabot-search huggingface dataset:
Department of Medical Ethics
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Women, Children Gain Ground in Solving Medical Bill Problems
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reflections on 21 years' experience with the carpal-tunnel syndrome
Authors: G. S. Phalen
Journal: JAMA (1970)

At the 99th annual meeting of the American Medical Association in 1950, I presented a report entitled "Spontaneous Compression of the Median Nerve at the Wrist," before the section on Orthopedic Surgery.<sup>1</sup>The report based on my experience with 11 patients with compression neuropathy of the median nerve at the wrist, was discussed by Walter Graham, MD, of Santa Barbara, Calif; Clarence Luckey, MD, of Stockton, Calif; and Sterling Bunnel, MD, of San Francisco. The report described a clinical syndrome unknown to almost all of the physicians attending that meeting. During the next six years, I continued to diagnose and treat patients with carpal-tunnel syndrome. With a series of 71 patients, I believed I could speak with some authority on the cause and the proper treatment of the condition. I again turned to the section on Orthopedic Surgery to present these data and statistics, during the 105th annual meeting
The Serologic Diagnosis of Disseminated Candidiasis in Patients with Acute Leukemia.
Authors: Harvey D. Preisler
Journal: Annals of Internal Medicine (1968)

s1 May 1968The Serologic Diagnosis of Disseminated Candidiasis in Patients with Acute Leukemia.Harvey D. Preisler, M.D., Herbert F. Hasenclever, Ph.D., Alexander A. Levitan, M.D.Harvey D. Preisler, M.D.Search for more papers by this author, Herbert F. Hasenclever, Ph.D.Search for more papers by this author, Alexander A. Levitan, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-68-5-1176_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDisseminated candidiasis is an increasingly important cause of morbidity and mortality in patients with leukemia. The incidence has been reported as 29%, 19%, and 12% (Bodey, 1966; Gruhn, 1963; Schumaker, 1964). The diagnosis, however, because of lack of adequate techniques for detection, is usually made on postmortem examination. In an attempt to facilitate the antemortem diagnosis of this disease the authors undertook a retrospective study to determine the presence of circulating agglutinating antibodies to heat-killedCandida albicans. Serial serum samples that were collected during the terminal 1 to 5 months of life of 33 patients who died with acute leukemia... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Harvey D. Preisler, M.D.; Herbert F. Hasenclever, Ph.D.; Alexander A. Levitan, M.D.Affiliations: Bethesda, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1968Volume 68, Issue 5Page: 1176-1176KeywordsAntibodiesAutopsyCandida albicansCandidiasisMorbidityMortalityRetrospective studies ePublished: 1 December 2008 Issue Published: 1 May 1968 PDF downloadLoading ...
Cancer of the Breast
Authors: John L. McClellan
Journal: JAMA (1996)

This is the fourth edition of an excellent text originally published in 1967. Since that original edition, understanding and treatment of breast cancer have undergone dramatic changes. The editors of this text and their chapter authors have done an excellent job of providing current information to the reader. The current edition has several new chapters, including those on benign breast diseases, oncogenes, legal issues, and community resources for patients. While the title remains<i>Cancer of the Breast</i>, the new chapters increase the utility of the text in the practice of general surgery and surgical oncology. For many surgical oncologists, the treatment of a primary breast cancer, while complicated, is easily understood. It is the woman with a breast complaint, in whom the diagnosis either is not clear or is not cancer, whose management and follow-up at times become confusing. By broadening the coverage, the usefulness of this textbook for the
Corrections and Clarifications: Working for Women's Health
Journal: Environmental Health Perspectives (2000)

provoke distaste in some medicalpractitioners, it nevertheless comprises an important duty; interestedparties and courts need expert, well- informed opinions as a basis for settling dis- putes.In the secondyear of "Grand Rounds in Environmental Medicine," we once again express our interest in receiving submissions that are educational, well written, and capa- ble ofwithstanding rigorouspeer review.
The long shadow of Flexner: a prolonged polemic in assessing outcomes in medical education
Authors: C. J. Martini
Journal: JAMA (1989)

Eighty-three years after the first recorded use of outcome measures in the evaluation of medical education, the US Secretary of Education has strengthened the outcome criterion for its recognition of accrediting agencies as follows<sup>1</sup>: The secretary determines whether an accrediting agency, in making its accrediting decisions, systematically obtains and considers substantial and accurate information on educational effectiveness... by determining that institutions or programs document the educational achievement of their students,... in verifiable and consistent ways, such as... graduate or professional school placements, job placement rates, licensing examination results, employer evaluations, and other recognized measures. At least one of these applications of outcome evaluation, the use of licensing examination results, would not have been accepted by Abraham Flexner in his time, although Dr Nathan P. Colwell, a former secretary of the American Medical Association (AMA) Council on Medical Education, surely would have felt vindicated. <h3>Colwell vs Flexner</h3> In 1906, the
Violence and War, with Clinical Studies. Volume VI: Science and Psychoanalysis.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
Authors: S. M. Gadgeel, J. C. Ruckdeschel, A. J. Wozniak, W. Chen, D. Hackstock, C. Galasso, A. Burger, S. P. Ivy, P. LoRusso, M. J. Edelman
Journal: Journal of Clinical Oncology (2011)

7564 Background: The role of anti-VEGF therapy in recurrent NSCLC is unclear. We are currently conducting a phase II trial evaluating cediranib, an oral inhibitor of VEGFR 1, 2 and 3, and pemetrexed in recurrent NSCLC pts who may or may not have previously received bevacizumab. Methods: Pts with progressive NSCLC following 1 or 2 prior regimens and with any histologic sub-type were eligible. Pts on anti-coagulants and with treated brain mets were allowed. Pts received cediranib 30mg daily. 1 week after starting cediranib, pts received pemetrexed 500 mg/m2 every 21 days. The study consists of two cohorts- A (no prior bevacizumab) and B (prior bevacizumab). Planned accrual is 37 pts each cohort. Accrual to cohort A is completed. Consenting pts underwent blood draw for circulating tumor cells (CTCs) and circulating endothelial cells (CECs) before therapy, 1 week after cediranib was commenced, and after 1 cycle of the combination. Results: 38 pts were enrolled in cohort A. Median age- 62, males- 50%, ever smokers- 92%, squamous- 18% (7 patients), brain mets- 34%, 2 prior regimens- 42%. Median cycles- 4 (range: 0-26). Grade 3/4 toxicities- neutropenia- 14%, febrile neutropenia- 5%, fatigue-22%, diarrhea- 14%, infection- 8%. One patient each developed pulmonary hemorrhage, cardiac ischemia and cerebrovascular event. Three deaths were deemed related to drug related toxicities. Response rate is 29% (95% CI: 17%-45%) and disease control rate (response+stable disease) is 74% (58%-85%). Median PFS is 5.6 (4.4-6.8) months and median survival is 11 (5.8-16.6) months. Efficacy parameters for squamous versus non-squamous were- Response rate- 0% vs. 35%, PFS- 3.7 vs. 5.7 months, survival 5.2 vs. 11.5 months. Among 18 pts with available data, 60% had decrease in CTCs and 31% of the patients had declines in CECs. There was no significant association between declines in CTCs or CECs and PFS. Conclusions: 1.The combination of cediranib and pemetrexed is tolerable. 2. The response rate of 29% (35%-non-squamous) and the median PFS of 5.6 (5.7-non-squamous) months are very promising. 3. Though the numbers are small, this combination is ineffective in recurrent squamous cell patients. 4. Enrollment to cohort B is ongoing.
European Perspectives
Journal: Circulation (2007)

T o acquire a post as a consultant cardiologist in the United Kingdom (UK), an aspiring physician will have successfully negotiated an "obstacle course" that involves critical decisions at a number of key stages.He or she will have competed for and obtained a cardiology post with a National Training Number (NTN), undertaken some original research, been trained in a chosen subspeciality, possibly worked for a year in another country, satisfied the local deanery in annual checks (Regional In-service Training Assessments), satisfied the national assessors for cardiology in a penultimate-year assessment (carried out by the Joint Committee on Higher Medical Training [JCHMT]/Specialist Advisory Committee for Cardiology [SAC]), obtained a Certificate of Specialist Training, and been entered on the General Medical Council (GMC) register of specialists.It can be a gruelling process, but at all stages the trainee is under the direction of the regional programme director for cardiology and has access to a welter of other sources of advice.Apart from the obvious requirements of "learning the trade," acquiring the necessary experience, and conducting the requisite number of specialist procedures (eg, exercise tests, angiograms, and echocardiograms, as recorded in a logbook), cardiologists who secure a consultancy must possess a range of personal qualities to pass the finishing line-or maybe it is the starting line?The JCHMT recognises that cardiology is believed to be "the most high-profile and practical skill-based of the medical specialities" 1 and suggests that successful practitioners need to be "decisive, competitive," and enjoy working as part of a team, especially with surgeons and nurse consultants. Trained Outside Britain?Cardiologists trained outside the UK may apply for posts in the UK, but they must first apply to the Postgraduate Medical Education and Training Board 2 (PMETB) for direct entry to the GMC register of specialists.The PMETB is a governmentfunded, statutory, independent body that was set up for all specialities in 2005 to, among other tasks, vet applications to practice in Britain.For cardiology, it has formally adopted the authority formerly held by the Royal Colleges of Physicians, which in fact are now commissioned by PMETB to perform the detailed evaluations required.A portfolio of evidence demonstrating experience, training, qualifications and competence similar to those required for trainees to acquire their Certificate of Specialist Training must be presented to PMETB.In addition, a doctor's knowledge and experience, wherever gained, can now be taken into account when considering his or her application, along with training or qualifications.The relevant British legislation for cardiologists trained outside the UK is Article 14 of the General and Specialist Medical Practice (Medical Education, Training and Qualifications) Order 2003.
Marine Algal Toxins: Origins, Health Effects, and Their Increased Occurrence
Authors: Frances M. Van Dolah
Journal: Environmental Health Perspectives (2000)

Certain marine algae produce potent toxins that impact human health through the consumption of contaminated shellfish and finfish and through water or aerosol exposure.Over the past three decades, the frequency and global distribution of toxic algal incidents appear to have increased, and human intoxications from novel algal sources have occurred.This increase is of particular concern, since it parallels recent evidence of large-scale ecologic disturbances that coincide with trends in global warming.The extent to which human activities have contributed to their increase therefore comes into question.This review summarizes the origins and health effects of marine algal toxins, as well as changes in their current global distribution, and examines possible causes for the recent increase in their occurrence.
Reply
Authors: D D K Rolston
Journal: Gut (1993)

Letters tubercular chemotherapy, but the duration of follow up and details of recurrence of obstruction are not given.Ileocaecal tuberculosis should be described as a separate entity from colonic tuberculosis.Anti-tubercular chemotherapy may be used as the primary treatment if a definite histological diagnosis of tuberculosis has been obtained, if there is no suspicion of malignancy, and if there is no intestinal obstruction; in all other cases surgical treatment should be offered.
THE COMPLAINT OF THE MANUFACTURING CHEMIST.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Résultats à long terme après pose de prothèses plastiques multiples pour sténoses pancréatiques réfractaires dans la pancréatite chronique
Journal: Endoscopy (2019)

Le traitement chirurgical des sténoses symptomatiques du canal pancréatique principal dans la pancréatite chronique est considéré comme plus efficace que la prise en charge endoscopique par prothèse en raison d’une efficacité à long terme supérieure.
The endogenous cannabinoid system protects against colonic inflammation
Authors: Federico Massa, Giovanni Marsicano, Heike Hermann, Astrid Cannich, Krisztina Monory, Benjamin F. Cravatt, Gian-Luca Ferri, Andrei Sibaev, Martin Storr, Beat Lutz
Journal: Journal of Clinical Investigation (2004)

Excessive inflammatory responses can emerge as a potential danger for organisms' health.Physiological balance between pro-and anti-inflammatory processes constitutes an important feature of responses against harmful events.Here, we show that cannabinoid receptors type 1 (CB1) mediate intrinsic protective signals that counteract proinflammatory responses.Both intrarectal infusion of 2,4-dinitrobenzene sulfonic acid (DNBS) and oral administration of dextrane sulfate sodium induced stronger inflammation in CB1-deficient mice (CB1 -/-) than in wild-type littermates (CB1 +/+ ). Treatment of wild-type mice with the specific CB1 antagonist N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3carboxamide (SR141716A) mimicked the phenotype of CB1 -/-mice, showing an acute requirement of CB1 receptors for protection from inflammation.Consistently, treatment with the cannabinoid receptor agonist R(-)-7-hydroxy-∆ ∆ 6 -tetra-hydrocannabinol-dimethylheptyl (HU210) or genetic ablation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in protection against DNBSinduced colitis.Electrophysiological recordings from circular smooth muscle cells, performed 8 hours after DNBS treatment, revealed spontaneous oscillatory action potentials in CB1 -/-but not in CB1 +/+ colons, indicating an early CB1-mediated control of inflammation-induced irritation of smooth muscle cells.DNBS treatment increased the percentage of myenteric neurons expressing CB1 receptors, suggesting an enhancement of cannabinoid signaling during colitis.Our results indicate that the endogenous cannabinoid system represents a promising therapeutic target for the treatment of intestinal disease conditions characterized by excessive inflammatory responses.Nonstandard abbreviations used: 2-arachidonoyl-glycerol (2-AG); cannabinoid receptor type 1 (CB1); cannabinoid receptor type 2 (CB2); dextrane sulfate sodium (DSS); 2,4-dinitrobenzene sulfonic acid (DNBS); fatty acid amide hydrolase (FAAH); hexa-decyl-trimethyl-ammonium bromide (HTAB); in situ hybridization (ISH); myeloperoxidase (MPO); N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716A); preproenkephalin (Enk); resting membrane potential (RMP); R(-)-7-hydroxy-∆ 6 -tetra-hydrocannabinoldimethylheptyl (HU210).
Commentaire de travail de J.-C. Saurin et al., pp. 1057
Journal: Endoscopy (2010)

See also: Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndromeEndoscopy 2010; 42(12): 1057-1062DOI: 10.1055/s-0030-1255742
The relationship of cadmium in the air to cardiovascular disease death rates
Authors: R. E. Carroll
Journal: JAMA (1966)

The average concentration of cadmium in the air of the 28 cities for which data are available shows a marked correlation with death rates from hypertension and arteriosclerotic heart disease (coefficient of correlation [r] =0.76). This association cannot be explained by a tendency of large, industrialized cities to have both high heart disease rates and heavily polluted air, since there is no correlation with indexes of air pollution in general. Zinc, a closely related element, is the only other pollutant which correlates significantly (r=0.56). Previous studies have shown that patients with hypertension have increased cadmium levels in their renal tissue, and that small amounts can produce hypertensive disease in rats. It is difficult to explain all the current knowledge about cadmium, except by the hypothesis that it is a significant cause of hypertension and perhaps of a portion of the rest of the cardiovascular disease spectrum.
New marrow transplant technique aids some cancers
Authors: M. L. Zoler
Journal: JAMA (1982)

Various groups in the United States and Europe are now performing bone marrow transplants using tissue whose undesirable components have been reduced in number immunologically so as to avert leukemia recurrence or graft-<i>v</i>-host disease (GVHD). Transplantation of bone marrow is an established technique in the hematologic restoration of patients with aplastic anemia (<i>JAMA</i>1981;245:1132-1139,<i>Br Med J</i>1982;285:835-837), certain leukemias (<i>JAMA</i>[MEDICAL NEWS] 1981;245:2484-2485), and some other disorders who have undergone marrow-ablative therapy. Until recently, however, the only possible donor in such a case was a sibling whose tissue was immunologically compatible with the patient's. According to Rainer Storb, MD, of the Fred Hutchinson Cancer Research Center in Seattle, only 25% to 40% of all patients have such siblings. But "with the advent of monoclonal antibodies" in the late 1970s, explains Roy Weiner, MD, director of the medical oncology program at the University of Florida College of Medicine, Gainesville, autologous
Characterization of single-nucleotide polymorphisms in coding regions of human genes
Authors: Michele Cargill, David Altshuler, James Ireland, Pamela Sklar, Kristin Ardlie, Nila Patil, Charles R. Lane, Esther P. Lim, Nilesh Kalyanaraman, James Nemesh, Liuda Ziaugra, Lisa Friedland, Alex Rolfe, Janet Warrington, Robert Lipshutz, George Q. Daley, Eric S. Lander
Journal: Nature Genetics (1999)